SCHEMBL25751700

SCHEMBL25751700

CC(C)(C)N=C(N1CCCC(c2cccnc2)C1)N1CCCC(c2cccnc2)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 1/20 0.49
▸ HSD11B1 P28845 2/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ CHRNA7 P36544 3/20 0.46
▸ CHRNB2 P17787 3/20 0.46
▸ CHRNA4 P43681 3/20 0.46
▸ CHRNB4 P30926 2/20 0.46
▸ CHRNA3 P32297 2/20 0.46
▸ CHRNA2 Q15822 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ HTR3E A5X5Y0 1/20 0.46
▸ PSIP1 O75475 1/20 0.46
▸ TRPA1 O75762 1/20 0.46
▸ HTR3B O95264 1/20 0.46
▸ CHRNA1 P02708 1/20 0.46
▸ CHRNG P07510 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ CHRNB1 P11230 1/20 0.46
▸ CYP2A6 P11509 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25767310 0.88 CYP11B2 (0.45) CYP11B2HSD11B1ALDH1A1CHRNA7CHRNB2
SCHEMBL25767313 0.82 CYP11B2 (0.49) CYP11B2HSD11B1ALDH1A1CHRNA7CHRNB2
SCHEMBL24059287 0.81 CYP11B2 (0.57) CYP11B2HSD11B1ALDH1A1CHRNA7CHRNB2
SCHEMBL17518824 0.79 CYP11B2 (0.54) CYP11B2HSD11B1ALDH1A1CHRNA7CHRNB2
SCHEMBL31339129 0.78 GPR119 (0.56) CYP11B2HSD11B1ALDH1A1CHRNA7CHRNB2
SCHEMBL25274630 0.78 GPR119 (0.56) CYP11B2HSD11B1ALDH1A1CHRNA7CHRNB2
SCHEMBL13841172 0.78 CYP11B2 (0.55) CYP11B2HSD11B1ALDH1A1CHRNA7CHRNB2
SCHEMBL14008938 0.77 HSD11B1 (0.57) CYP11B2HSD11B1ALDH1A1CHRNA7CHRNB2
SCHEMBL16144645 0.76 HSD11B1 (0.50) CYP11B2HSD11B1ALDH1A1CHRNA7CHRNB2
SCHEMBL17516264 0.76 HSD11B1 (0.50) CYP11B2HSD11B1ALDH1A1CHRNA7CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 — — US disclosed
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 — — US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 — — US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 — — US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RNGTT, NSUN2, ALKBH1 CYP11B2 4377/4885HSD11B1 4665/4885ALDH1A1 1901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback